Quality of Life and Health Economic Measurements in Allergic Patients Treated With Immunotherapy

Completed

• Conditions: Hypersensitivity; Asthma; Rhino-Conjunctivitis; Quality of Life; Effects of Immunotherapy

• Registration Number: NCT01486498
• Lead Sponsor: Aalborg University

Brief Summary

Grass pollen and house dust mites (HDM) are the most common allergens causing allergic rhino-conjunctivitis (RC) and/or asthma (A). Subcutaneous allergen specific immunotherapy (SCIT) reduces symptoms and use of medication. The purpose of SABAL is to assess the effect of SCIT on disease severity classifications in terms of number of days affected- and sick days on patients with grass pollen and/or HDM induced disease. These outcome measures will be gathered in one single measure: Quality Adjusted Life Years (QALY)

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Primary Completion: 2009-11
• Study Completion: 2011-11
• Status Verified: 2011-12
• Study First Submitted: 2011-12-03
• Study First Submitted QC: 2011-12-05
• Last Update Submitted: 2011-12-05
• Study First Posted: 2011-12-06
• Last Update Posted: 2011-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 571

Inclusion Criteria

• Adults (> 16 years) and allergic to grass pollen and/or house dust mites.

Exclusion Criteria

• Allergic patients who had been immunotherapy treated before.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified